Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

  • STATUS
    Recruiting
  • participants needed
    54
  • sponsor
    University of Pennsylvania
Send
Updated on 19 February 2024
See if I qualify
measurable disease
multiple myeloma

Summary

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Description

Tasquinimod has previously been studied as an anti-cancer agent in patients with other cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer that showed an improvement in radiographic progression-free survival. The side effect profile of tasquinimod is well-characterized based on this previous experience. This trial will establish a maximum tolerated dose and optimal schedule for administration of tasquinimod in patients with multiple myeloma and then investigate the maximum tolerated dose of tasquinimod in combination with a standard myeloma regimen of ixazomib, lenalidomide, and dexamethasone (IRd). For both single agent tasquinimod and the combination of tasquinimod with IRd, exploratory expansion cohorts will be enrolled to preliminarily characterize the antimyeloma activity of each regimen.

Details
Condition Multiple Myeloma, Multiple Myeloma, Lymphoproliferative Disorder
Age 18-100 years
Treatment Tasquinimod, IRd chemotherapy
Clinical Study IdentifierNCT04405167
SponsorUniversity of Pennsylvania
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'Signed informed consent'
b'18 years of age or older'
b'Multiple myeloma (MM) diagnosed according to IMWG criteria'
b'Measurable disease (this is defined differently in different arms)'
b'Multiple myeloma relapsed or refractory to treatment (this is defined differently in'
b'different arms)'
b'Meet certain clinical laboratory criteria'
b'ECOG performance status \\u22642'
b'Life expectancy of at least 3 months'
b'For women of childbearing potential, a negative serum or urine pregnancy test prior to'
b'tudy treatment.'
b'For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile'
b'(absence of ovaries and/or uterus): agreement to use two methods of contraception one'
b'of which must be highly effective'
b'For men: agreement to use a barrier method of contraception for 1 month before start'
b'of study treatment, during the treatment period and for 6 months after the last dose'
b'of study treatment.'

Exclusion Criteria

b'Failure to have fully recovered (i.e. \\u2264 Grade 1 toxicity) from the effects of prior'
b'chemotherapy (except for alopecia)'
b'Active graft versus host disease'
b'Treatment with any of the following:'
b'Cytotoxic chemotherapy within 3 weeks prior to the initiation of study treatment'
b'Proteasome inhibitors, Imids, or monoclonal antibodies within 2 weeks prior to'
b'the initiation of study treatment'
b'Experimental therapy within 4 weeks or 5 half-lives, whichever is shorter'
b'Systemic corticosteroids >=10 mg prednisone or equivalent within 7 days prior to'
b'the initiation of study treatment'
b'Radiotherapy within 7 days prior to initiating study treatment'
b'Plasmapheresis within 4 weeks prior to the initiation of study treatment'
b'Tasquinimod at any time'
b'Known central nervous system involvement by myeloma'
b'Diagnosis of smoldering multiple myeloma'
b'Diagnosis of POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,'
b'endocrinopathy, monoclonal protein, and skin changes)'
b'Active plasma cell leukemia'
b'Symptomatic primary (AL) amyloidosis'
b'Diagnosis of myelodysplastic syndrome or myeloproliferative syndrome'
b'Active other malignancy'
b'Major surgery within 4 weeks prior to initiating study treatment'
b'Evidence of severe or currently uncontrolled cardiovascular condition'
b'Ongoing or active systemic infection that requires systemic antibiotic or parenteral'
b'anti-infective therapy'
b'Active tuberculosis, active hepatitis A, B or C virus infection, or known human'
b'immunodeficiency virus (HIV) positive'
b'History of pancreatitis'
b'History of malabsorption or other condition that would interfere with absorption of'
b'tudy drugs'
b'Systemic treatment within 14 days prior to the initiation of study treatment with'
b'moderate or strong inhibitor or moderate or strong inducer of cytochrome P-3A4'
b'(CYP3A4)'
b'Need for ongoing therapy drug substances of narrow therapeutic range that are'
b'metabolized mainly by CYP3A4 (alfentanil, fentanyl, quinidine, astemizole,'
b'terfenadine, sirolimus, tacrolimus, cyclosporine, cisapride, ergotamine)'
b'Need for ongoing therapy with drug substances of narrow therapeutic range metabolized'
b'mainly by CYP1A2 (duloxetine, alosetron, theophylline, tizanidine, ondansetron)'
b'Ongoing treatment with warfarin, unless the INR is <=3.0.'
b'For subjects enrolled on the IRd combination arms, prior dose-limiting toxicity with'
b'lenalidomide or ixazomib or absolute contraindication to concomitant thrombosis'
b'prophylaxis'
b'Peripheral neuropathy grade \\u22652 (NCI-CTCAE)'
b'Known hypersensitivity to tasquinimod or any excipients in the study treatments'
b'Pregnant or nursing (lactating) women'
b"Any other condition that would, in the Investigator's judgment, contraindicate"
b"ubject's participation in the clinical study due to safety concerns or compliance"
b'with clinical study procedures'
b'Prior inclusion in this study'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

measurable disease
multiple myeloma

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.